Kogenate
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Kogenate (recombinant factor VIII [rfVIII]; Bayer/CSL Behring) – is a recombinant antihemophilic factor indicated for the control and prevention of bleeding episodes, perioperative management, and for routine prophylaxis in children and adults. Kogenate is produced using the baby hamster kidney cell line. Although the cell culture medium used in the manufacturing of Kogenate does not contain any proteins of animal origin, the cell culture medium does contain human proteins. The current formulation, Kogenate FS, is formulated with sucrose and has been available since 2000. This makes it a second-generation rfVIII, while the original therapy contained human albumin as a stabilizer and was thus initially classified as a first-generation recombinant product
Under an agreement that involved global distribution through 2017, Bayer distributed Kogenate to CSL Behring, which additionally markets it under the tradename Helixate in the US. In Europe, Bayer and CSL Behring market the product under the tradename Helixate NexGen. However, the manufacture of the Helixate brand is now being stopped and the product phased out, as CSL Behring transitions its patients onto Afstyla (single-chain rfVIII; CSL Behring).
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Kogenate : Hemophilia
LIST OF FIGURES
9 Figure 1: Kogenate for hemophilia – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Kogenate for hemophilia
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Kogenate for hemophilia
13 Figure 4: Kogenate sales for hemophilia across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES
6 Table 1: Kogenate drug profile
7 Table 2: Kogenate pivotal trial data in hemophilia
14 Table 3: Kogenate sales for hemophilia across the US, Japan, and five major EU markets, by country ($m), 2016–25
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Vonvendi 
Sign up to the